Innovation
Collaboration with US universities UCSF/UC Berkeley
The Laboratory for Genomics Research to foster innovative technologies
Our R&D Approach
We are at the forefront of health-related advances in science and technology, working to create innovative solutions to a range of healthcare challenges.
We’re combining the power of genetic and genomic insights into what causes disease, with the speed and scale of artificial intelligence and machine learning (AI/ML) to make better predictions about who a treatment might work for, and why.
We believe this powerful combination of data and technology holds the key to fundamentally transforming medical discovery for the better, improving R&D success rates and shaping how even the most challenging diseases, like neurological conditions and cancer, can be both prevented and treated.
There’s never been a time when science and technology have formed such a powerful union as they do now. We’re able to identify drug discovery targets using genomics and AI/ML in a way that is unprecedented. We’re also able to use more approaches than ever before to design new vaccines and medicines to address the root cause of disease.
Tony Wood
We are investing in our capabilities with 20 sites in the United States, including seven R&D facilities focused on innovation.
Our pipeline
As a global biopharma company, we invest heavily in our industry-leading pipeline of new products and specialty medicines that help us to get ahead of disease together.
Our Partnerships
Working with our partners to deliver the next generation of transformational vaccines and medicines
Therapeutic areas
We prioritize innovation to make the world’s diseases a thing of the past.
To get ahead of disease, we prioritize research into vaccines and medicines across our four therapeutic areas. We also remain open to opportunities outside these core areas where the science aligns with our strategic approach.
Explore more about our therapeutic areas on our global website, below.
